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Abstract 
Background – Appropriate thromboprophylaxis for patients with atrial fibrillation (AF) 
remains a national challenge. 
Methods– We hypothesized that provision of decision support in the form of an Atrial 
Fibrillation Decision Support Tool (AFDST) would improve thromboprophylaxis for AF 
patients. We conducted a cluster randomized trial involving 15 primary care practices 
and 1,493 adults with non-valvular AF in an integrated healthcare system between April 
2014 and February 2015. Physicians in the intervention group received patient-level 
treatment recommendations made by the AFDST. Our primary outcome was the 
proportion of patients with antithrombotic therapy that was discordant from AFDST 
recommendation. 
Results – Treatment was discordant in 42% of 801 patients in the intervention group. 
Physicians reviewed reports for 240 patients. Among these patients thromboprophylaxis 
was discordant in 63%, decreasing to 59% 1 year later (p=0.02). In non-stratified 
analyses changes in discordant care were not significantly different between the 
intervention group and control groups. In multivariate regression models assignment to 
the intervention group resulted in a non-significant trend towards decreased 
discordance (p=0.29), being a patient of a resident physician (p=0.02), and a higher 
HASBLED score predicted decreased discordance (p=0.03), while female gender 
(p=0.01) and a higher CHADSVASc score (p=0.10) predicted increased discordance.  
Conclusions – Among patients whose physicians reviewed recommendations of the 
decision support tool discordant therapy decreased significantly over 1 year. However, 
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in non-stratified analyses the intervention did not result in significant improvements in 
discordant antithrombotic therapy. 
Key words: atrial fibrillation, anticoagulation, performance improvement, decision 
support, warfarin, novel oral anticoagulants, aspirin. 
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Introduction 
Atrial fibrillation (AF) is the most common significant cardiac rhythm disorder and is also 
a powerful common risk factor for stroke: about 15% of all strokes in the U.S. are 
attributable to AF. With the aging of the U.S. population, the prevalence of atrial 
fibrillation (AF) will increase substantially from over 2.2 million to more than 3 million by 
the year 2020.1  
Numerous randomized trials have established that anticoagulation can significantly 
reduce the stroke risk posed by AF. However, studies have documented widespread 
underutilization of this therapy, or, at times, inappropriate use. A recent systematic 
review comparing current treatment practices for stroke prevention in AF with published 
guidelines showed underuse of oral anticoagulants in high risk patients in the majority of 
54 studies reviewed.2 Among patients in 29 studies with a history of prior stroke or 
transient ischemic attack (TIA) who should all be receiving anticoagulant therapy, 
treatment levels averaged less than 60% (range 19% - 81.3%). Among high risk 
patients with a CHADS2 score ≥ 2 treatment levels averaged less than 70% (range 39% 
- 92.3%). While there has been a trend towards improvement in utilization of 
anticoagulant therapy over the past decade, a recently published study of community-
based practices in the Christiana Care Health System in northern Delaware continued 
to show substantial underutilization with almost one-third of high risk patients (CHADS2 
score ≥ 2) never receiving anticoagulant therapy despite the absence of identified 
barriers to such treatment.3 
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Furthermore, guidelines for thromboprophylaxis in patients with AF focus predominantly 
on stroke risk as calculated by either the CHADS2 or the CHA2DS2VASc scores and do 
not integrate bleeding risk in an explicit, quantitative manner.4, 5 As a result, clinicians 
may still struggle to decide whether oral anticoagulant therapy will yield a net benefit for 
any given patient. 
Our hypothesis was that provision of computerized decision support for individual 
patient-level decision-making about oral anticoagulant therapy would improve decision-
making and thromboprophylaxis for AF patients in our system’s primary care network. 
To explore this hypothesis we tested the incremental impact of adding a quality-
improvement (QI) intervention to an educational package (for practice staff and 
clinicians) using a computerized aid, the Atrial Fibrillation Decision Support Tool 
(AFDST) for individual patient-level decision-making about oral anticoagulant therapy in 
patients with non-valvular AF.  
 
Methods 
We used our health system’s clinical data store to identify 9,270 patients with an 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM), diagnosis of atrial fibrillation (427.31) or atrial flutter (427.32) who did not have 
diagnoses of mitral valve disease (394.x), aortic valve disease (395.x), heart valve 
transplant (V42.2) or heart valve replacement (V42.3) in their active problem list. The 
data pull to form our inception cohort was performed in February of 2014. Since our 
university hospital is a tertiary/quaternary care center, many patients who are 
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hospitalized in our health system do not have outpatient care delivered in our system. 
Thus, only 4,021 of these patients were seen in any of the outpatient practices in our 
health system. Finally, many patients receiving specialty care in our system do not 
receive primary care in our system, thus only 1,577 were seen in the Primary Care 
Network (PCN). Figure 1 details the major steps and the study flow. The institutional 
review board at the University of Cincinnati approved this study. 
Information needed to calculate stroke risk using CHA2DS2VASc
6, major hemorrhage 
using HAS-BLED7, and intracerebral hemorrhage (ICH)7, was extracted from the clinical 
data store using the active problem list and a combination of laboratory values and 
clinical measurements. Time in therapeutic range, needed to calculate the HAS-BLED 
score, was determined by interpolating INR values through time over the past one year, 
similar to the Rosendaal method.8  Current antithrombotic therapy (oral anticoagulant or 
antiplatelet therapy) was retrieved from the active medication list. Data were stored on a 
secure server at our Center for Health Informatics as discrete elements hosted on 
MYSQL™. SAS data files were created as necessary for statistical analyses using 
unique coded patient identifiers.  Further details are described separately.9 
ATRIAL FIBRILLATION DECISION SUPPORT TOOL (AFDST) - 
Treatment recommendations were made by an Atrial Fibrillation Decision Support Tool 
(AFDST) based on projections for quality-adjusted life years (QALYs) calculated by a 
decision analytic model that integrates patient-specific risk factors for stroke and 
hemorrhage and examines strategies of no antithrombotic therapy, aspirin, or oral 
anticoagulation.9, 10  The strategy recommended by the AFDST was the one resulting in 
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the largest expected utility in QALYs. Decision model construction and analysis was 
done using a standard computer program (Decision Maker, Boston, Massachusetts).  
Development and Dissemination of Didactic Materials - 
Clinician experts on the team developed a set of major topics and from that a 2-session 
conference series. This educational package was delivered as 2 didactic noon- 
conferences on AF with a review of up-to-date anticoagulation guidelines for stroke 
prevention, and distribution of educational materials (e.g., pocket cards with 
CHA2DS2VASc stroke risk assessment and HAS BLED risk factors). AMA Category 1 
PRA credit and/or AAFP Prescribed Credit was provided for conference attendence. 
Speakers visiting the primary care sites included 3 stroke neurologists, 2 cardiologists, 
and a general internist (PI) who were co-investigators in this study. Faculty and 
residents in the Department of Internal Medicine at the University of Cincinnati also had 
an opportunity to participate in the first of the noon conferences as a Grand Rounds 
lecture delivered by the PI. All practices (intervention and control groups) participated in 
the conference series.  
Design of the Clinical Trial –  
We cluster randomized practices to an intervention and control group. Six practices 
containing 35 clinicians and 801 patients with AF served as the intervention group, while 
9 practices containing 35 clinicians and 692 patients were randomized to the control 
group. 
Physicians and practice managers in the intervention group were provided access to a 
physician-level and practice-level summary report highlighting patients whose current 
therapy was discordant with treatment recommendations of the AFDST, along with an 
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explanation for the recommendation that included the gain or loss in QALE predicted by 
the decision model and the 2014 ACC/AHA/HRS guidelines.4 Physicians were 
encouraged to revisit the anticoagulation decision in these patients, and work flows to 
facilitate this were developed in collaboration with the UCHealth Quality Manager and 
local practice leadership. The culmination of this preparatory work was a retreat in 
which lead physicians and managers from all practices, including both intervention and 
control group practices, were invited. At the retreat we presented and discussed an 
early prototype of the report, received feedback and modified the report.  
We next developed a secure web site which we used to communicate patient 
information to the clinicians in the intervention arm. Physicians who had patients with 
current treatment that was discordant from the AFDST recommendation received an 
email with a personal login and password to the website. The initial login screen 
provided an overview of the performance improvement initiative (see Supplemental 
Figure 1). Clinicians were asked to review and corroborate clinical risk factors and 
current treatment obtained from the Clarity® database to insure accuracy (Figure 2.) 
Clinical information obtained from the electronic health record was highlighted by a 
check mark in the column to the far left, labeled “EPIC”, and by bolding of the text. 
Detailed definitions for clinical variables and risk factors were provided at the far right of 
the screen. Clinicians could correct inaccurate information by adding or deleting 
treatments and/or risk factors. If changes were made, the patient’s recommendation 
was reanalyzed by the AFDST and reposted. If no changes were required a screen 
reviewing the confirmed clinical risk factors appeared (see Supplemental Figure 2). 
From this screen, clinicians could immediately generate a 2-page report. The first page 
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contained a review of the CHA2DS2VASc, CHADS2, and HAS-BLED scores along with 
the physician’s and patient’s names (Figure 4). The second page (Figure 4) was the 
worksheet which reviewed the clinical factors upon which the stroke and bleeding risk 
scores were calculated, the patient’s CHA2DS2VASc, CHADS2, and HAS-BLED scores, 
and the patient-specific projections for quality-adjusted life expectancy with each of 
three strategies – no treatment, oral anticoagulant therapy, and aspirin. The far right 
side of the worksheet contained a condensed summary of the 2014 ACC/AHA/HRS 
guideline. The appropriate recommendation for each patient was highlighted based 
upon the CHA2DS2VASc score. In order to get feedback on the design and functionality 
of the secure web site and optimize work flow within the practices, we pilot tested the 
tool and intervention. We used feedback from the pilot to revise our processes and the 
web site and report design. After completing the pilot phase and updating our processes 
and report format, we extended the performance improvement project to the remaining 
5 practices in the intervention group on April 2, 2014.  
Performance Improvement Procedures - 
We implemented the following processes for the intervention practices. Our study 
coordinator reviewed a report from our EHR every Friday summarizing the next week’s 
scheduled visits for patients whose current therapy was discordant with the AFDST 
treatment recommendation. Practice managers had been instructed to maintain a 
“tickler file” of printed reports and these were given to the appropriate physician on the 
morning of a patient’s visit. Our study coordinator also received a report from the EHR 
every Friday that summarized all scheduled patient visits on her list that have been 
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completed in the prior week. This was used to trigger an email to the physician with a 
link to a REDCap® survey. 
Data Analysis  
Our initial power calculations were based on an estimate of 410 patients in each the 
intervention and the control group.  Using a two-tailed alpha of 0.05, for our primary 
outcome, discordance between decision support tool recommendation and actual 
treatment, we estimated we would have 80% power to detect a 9.4 percentage-point 
difference between the two groups before controlling for pre- vs. post-intervention 
correlations. Since we expected a high pre-post consistency in “appropriate” prescribing 
within patients (.8 to .9), we adjusted our power estimates. After adjusting for 
“appropriate” prescribing prior to the intervention, we estimated that we would have 80% 
power to detect a difference of approximately 4.7 percentage-points between groups. 
SAS was used to perform simple descriptive statistical analyses and to develop 
multivariable regression models.  All reported p-values are derived from models in 
which the provider is a random factor and denominator degrees of freedom are based 
on numbers of patients.  The study alpha was a two-tailed p = .05, unadjusted for 
multiple tests. 
Funding Source 
Support for this study came from the Pfizer Educational Group, Bristol-Myers 
Squibb/Pfizer Education Consortium, and NIH/NCATS grant 8 UL1 TR000077-05. The 
corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication. The authors are solely 
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responsible for the design and conduct of this study, all study analyses, the drafting and 
editing of the paper and its final contents. 
Results 
Characteristics of patients and practices in each of the arms of the study are described 
in Table 1. Results are only reported for patients who were part of the inception cohort 
formed in 2014. The 84 patients who died over the year were censored from these 
numbers. For the most part, patients in both groups were demographically comparable 
and a similar proportion were receiving oral anticoagulant therapy (OAT). There was a 
slightly higher proportion of faculty members and a lower proportion of residents in the 
control practices. There was a higher proportion of family medicine and medicine-
pediatrics physicians in the control group and a higher proportion of internal medicine 
physicians in the intervention group. 
 
Changes in discordant prescribing of antithrombotic therapy among physicians who 
used the AFDST –  
Among physicians in the intervention group, we first looked at the impact of whether the 
physician used the tool and reviewed the AFDST report. Recommendations of the 
AFDST were reviewed for a total of 240 patients. Among those patients, there was a 
significant decrease in the proportion with discordant care, declining from 63.3% in 2014 
to 58.3% in 2015. 
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Changes in discordant prescribing of antithrombotic therapy – How did the overall 
proportion of patients with discordant treatment change between 2014 and 2015? 
For the UCHealth PCN practices overall (see Table 2), the proportion of patients whose 
treatment was discordant with the recommendations of the AFDST dropped from 41.9% 
(626/1493) to 40.6% (606/1493), p=0.10. At baseline, 41.8% (335/801) of the 
intervention practices’ patients had discordant care, while 42.1% (291/692) of patients in 
the control practices had care that was discordant from AFDST recommendations. At 
one year follow-up, the proportion of patients with discordant care dropped to 41.1% 
(329/801) and 40% (277/692) in the intervention and control practices, respectively.  
When we looked at subgroups based upon the AFDST recommendation, we did not see 
significant differences. Table 2 further describes whether discordant treatment was due 
to over or under-treatment. Of greatest interest, discordant care due to under-treatment 
(aspirin or no oral anticoagulant therapy among patients for whom the AFDST 
recommended oral anticoagulant therapy) did not change significantly in either the 
intervention or control practices going from 44.7% to 44.5% (baseline -> 1 year f/u) in 
the intervention practices (p=0.59), and from 44.8% to 43.5% (p=0.27) in the control 
practices. 
Table 3 reports how treatment discordance changed over time, stratified by subgroups 
describing practice and physician characteristics. Practice characteristics included an 
assessment of their readiness for change and enthusiasm for participating in 
performance improvement (PI) activities. This assessment was made by the director of 
performance improvement for the Primary Care Network on a 3-item scale ranging from 
high enthusiasm to low enthusiasm. There was a provocative but statistically 
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insignificant trend towards a larger decrease in discordant therapy among the practices 
with a high level of enthusiasm for PI work. Physician characteristics included faculty 
type (academic faculty, non-faculty, or resident) and specialty. There was a significant 
decrease in discordant care among academic faculty. In addition, there was an 
interesting trend among residents, with discordant therapy decreasing from 44.2% in 
2014 to 39.5% in 2015. Although the p-value did not reach statistical significance, the 
total number of patients cared for by the residents was only 172, the smallest sub-group 
of the category. When physicians were categorized by specialty (Internal Medicine, 
Family Medicine, or Medicine-Pediatrics), only the Medicine-Pediatrics physicians had a 
significant decrease in discordant care, from 47.7% in 2014 to 40.9% in 2015.  
 
Improvement in thromboprophylaxis – What proportion of patients with discordant 
treatment in 2014 had “appropriate” thromboprophylaxis in 2015? 
We next looked at patients who had discordant treatment in 2014 to see what proportion 
improved and had “appropriate” thromboprophylaxis in 2015. As shown in Table 4, 
“appropriate” treatment in 2015 was not significantly different between the intervention 
and control practices. Looking at practice sites, there was an interesting, but statistically 
insignificant trend towards a clinically meaningful improvement in AFDST-consistent 
treatment in the Internal Medicine Resident practice, with 25.4% having “appropriate” 
thromboprophylaxis in 2015. Looking at practice readiness for change and enthusiasm 
to participate in PI activities, the practices rated as having low enthusiasm had the 
lowest proportion with AFDST-consistent treatment in 2015, but the differences were 
not significant. Looking at type of faculty, there was a significantly higher proportion of 
“appropriate” thromboprophylaxis among resident physicians (25%) and faculty (13%) 
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compared with non-faculty (7%) physicians. Looking at physician specialty, there was a 
significantly higher proportion of patients with “appropriate” thromboprophylaxis among 
Medicine-Pediatrics physicians (21.4%), compared with Internal Medicine (11.8%) and 
Family Medicine (12%). 
 
Changes in Treatment Recommendations Over Time - 
For this analysis we wished to determine how often physicians reacted to changes in 
patients’ clinical status that resulted in a changed AFDST recommendation over the 1-
year follow-up period. For instance, the occurrence of a major bleed and the resultant 
increase in the HASBLED score could alter the balance of risk and benefit such that oral 
anticoagulant therapy is no longer recommended. Similarly, if a patient developed new 
risk factors for stroke, the AFDST recommendation could change from either no 
antithrombotic therapy or aspirin to oral anticoagulation. Although these events did not 
occur often, we found that clinicians rarely responded to these significant clinical 
developments. AFDST recommendations changed from Oral Anticoagulant Therapy to 
No Antithrombotic Therapy in 11 patients (see Supplemental Table 5). Of the 7 patients 
who were receiving oral anticoagulant therapy in 2014, treatment was changed to no 
antithrombotic therapy in 3, to aspirin in 1, and not changed in 3. AFDST 
recommendations changed from No Antithrombotic Therapy to Oral Anticoagulant 
Therapy in a total of 34 patients (see Supplemental Table 6). Of the 8 patients who 
were receiving no antithrombotic therapy in 2014, 2 were switched to oral 
anticoagulation, 1 was switched to aspirin, and 5 remained on no antithrombotic 
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therapy. These results underscore that changes in patients’ clinical status that warrant a 
reconsideration of antithrombotic therapy are likely not being recognized or acted upon. 
 
Post-Visit Survey of Primary Care Physicians –  
The project coordinator submitted a weekly list of discordant AF patients who had been 
seen by their primary care provider to the project evaluator.  An e-mail containing a link 
to a REDCap® survey was sent to providers asking them to provide an assessment of 
the recent patient encounter. Slightly more than half (51.6%) of these surveys were 
returned by the providers. The survey found that over 70% of these providers received 
the AFDST recommendations and report prior to the patient visit and almost all of those 
providers (68.8% of 70.1%) reviewed the report prior to seeing the patient (see 
Supplemental Table 7). Over half of the providers (51.1%) discussed anticoagulation 
treatment with their patients, however, only a small percentage (6.3%) actually made a 
change in therapy at that visit. 
Providers were asked to comment on why they did not make recommended changes in 
antithrombotic therapy. The most frequent explanations were:  “patient preferences” 
(26.7%) and “specialists are managing anticoagulation therapy” (24.4%).  Cost was 
never indicated as a reason for not changing therapy.  Interestingly, 9% of respondents 
indicated that they did not change therapy because they disagreed the decision support 
tool recommendation.  Providers were given an opportunity to make general comments.  
Several indicated that the tool was cumbersome or could be improved.  A number of 
clinicians mentioned concerns about increased fall risk in some of their elderly patients, 
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or that the patient was not currently in AF, or that the patient was being managed by a 
cardiologist and they didn’t want to change the cardiologist’s treatment decision.   
 
Discussion 
A randomized controlled trial examining the impact of implementing the Atrial Fibrillation 
Decision Support Tool demonstrated no significant improvement in discordant 
antithrombotic therapy compared with a group of control practices that did not receive 
the tool. However, discordant therapy decreased significantly over a 1-year period of 
time for patients whose physicians actually reviewed the reports and recommendations 
of the decision support tool. This suggests that the AFDST can have a beneficial impact 
on clinical care if it is used.  
There are many potential explanations for the less than expected impact of our PI 
intervention. Most obvious is the nuance and complexity of real-world clinical situations. 
In interviews with physicians who used the tool, a common explanation for 
antithrombotic therapy decisions that were discordant with both AFDST and ACC/AHA 
guideline recommendations was that their patients had many competing medical 
problems that increased the risk of bleeding and complicated the decision-making 
process. These competing clinical issues included among others, frailty, a history of 
frequent falls, and other significant comorbidities that limited life expectancy and/or 
quality of life. Many of these physicians added however, that even if they didn’t change 
treatment, they found it useful to review their patient’s situation. Many indicated that use 
of the AFDST prompted them to have a discussion about treatment choice with their 
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patient(s). An unexpected issue was that many primary care physicians indicated they 
were not making antithrombotic therapy decisions for their AF patients; rather they were 
deferring these decisions to their cardiologist colleagues. In other cases, patients had 
been discharged from an inpatient setting already started or not on an antithrombotic 
therapy and the primary care physicians felt that the decisions had already been made. 
Another issue we suspect played a role was therapeutic or clinical inertia.41-44 Clinical 
inertia is a particular challenge in the management of chronic diseases and may 
contribute to hesitancy or delays in intensifying therapies. While making an initial 
therapeutic decision is hard enough, it is even more difficult to get clinicians to 
reconsider treatment decisions once made. This is what we asked them to do by 
reviewing the antithrombotic therapy decision in patients with prevalent rather than 
newly incident AF. Relevant to this point, we found that the treatment recommendation 
made by the AFDST changed over the 1-year follow-up period in 45 patients. We also 
found that physicians responded to these changes in the clinical balance of risk factors 
by changing treatment in only a minority of cases, identifying another important gap in 
clinical care and decision-making. Prompting physicians to reconsider their 
thromboprophylaxis decision by targeting decision support exclusively on these fewer 
but more relevant cases may be a more effective approach. Finally, a number of 
physicians commented about the difficulty of using a separate, non-integrated web-site 
for the AFDST. They suggested that it would be more convenient to have the decision 
support tool fully integrated as part of the EHR.  
What have we learned from this study that might improve the useful and effectiveness 
of the AFDST? First, we must minimize all barriers to the use of decision support tools. 
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For purposes of the study, we housed the tool in a separate and secure website. 
However, clinicians want and need to be able to access these tools as part of the 
natural flow of patient care. Thus, tools such as the AFDST need to be embedded within 
our electronic health records so they can be accessed seamlessly. Indeed, we are 
currently doing this, embedding the AFDST as a point of care tool within our Epic EHR 
installation which will enable clinicians to access the tool in real time, when they need it! 
We also need to avoid overwhelming our clinicians with too many tasks and too much 
information at once. Some of the physicians in our study were asked to review as many 
as 40 patients with prevalent AF. Can we better target high yield clinical situations and 
only generate alerts or clinical reminders in those cases? As discussed above, these 
situations may include notifying clinicians when the risk factor profile has changed and 
their current approach to thromboprophylaxis is no longer optimal instead of burdening 
physicians with a long list of every patient who might conceivably benefit from revisiting 
the thromboprophylaxis decision. In addition, the strength of the AFDST 
recommendation is related to the magnitude of the gain or loss in quality-adjusted life 
expectancy were optimal thromboprophylaxis used. Generating clinical reminders or 
alerts only when the potential clinical benefit exceeds a higher, predetermined threshold 
might be a better approach. Are primary care physicians the right audience for providing 
decision support for AF thromboprophylaxis? We took the approach of providing 
decision support broadly for a wide swath of clinicians. Some of our primary care 
physicians, particularly non-faculty providers were not comfortable making these 
decisions. Given the likely decline in the numbers of patients taking warfarin for AF 
thromboprophylaxis in the era of 4 new oral anticoagulants, perhaps we should retool 
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our pharmacy-based coumadin clinics, and turn them into thromboprophylaxis 
consultation services. Indeed, funneling patients to a small number of highly trained and 
experienced clinicians, such as our clinical pharmacists who have been staffing 
anticoagulation clinics and providing them with decision support tools such as the 
AFDST may be a more effective strategy. 
 
Conclusions 
A randomized controlled trial examining the impact of implementing an AFDST found 
that among patients whose physicians actually reviewed the reports and 
recommendations of the decision support tool, discordant therapy decreased 
significantly over a 1-year period of time. However, in non-stratified analyses the 
intervention did not result in significant improvements in discordant antithrombotic 
therapy.  These findings suggest next steps we must take to decrease barriers to the 
convenient and more effective use of the AFDST, perhaps by improving its integration 
into the EHR as a fully embedded application; by better targeting high yield clinical 
situations (i.e., generating best practice alerts within the EHR only when evolution in 
clinical risk factors results in a recommendation change by the decision support tool) 
instead of asking physicians to review all AF patients with discordant therapy; and finally 
to consider targeting additional clinician groups as decision makers, such as 
cardiologists and clinical pharmacists in addition to primary care physicians; and 
focusing on decision-making for incident rather than prevalent AF, when initial 
therapeutic decisions are first being made. 
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Figure Legends - 
Figure 1. Experimental design and study flow. 
Figure 2. Epic data verification screen for a single patient. 
Figure 3. Title page for patient report. 
Figure 4. Patient report containing review of clinical data and risk factors, 
CHA2DS2VASc, CHADS2, and HAS-BLED scores, AFDST treatment recommendation, 
and AHA/ACC/HRS guideline 
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Table 1. Patient and Practice Characteristics 
 Intervention Practices Control Practices 
Patient Characteristics   
Number 801 692 
Age (mean) 70.2 69.8                     (p=0.56) 
Female (%) 44 48                        (p=0.19) 
CHA2DS2VASc (mean) 3.60 3.74                     (p=0.14) 
HAS-BLED (mean) 2.07 2.18                     (p=0.06) 
Proportion receiving oral 
anticoagulant therapy (%) 
50 50                        (p=0.92) 
   
Practice Characteristics   
Faculty (%) 37 47                      (p=0.05) 
Non-Faculty (%) 12 24                             “ 
Residents (%) 51 29                             “ 
   
Internal Medicine 88 13                    (p<0.0001) 
Family Medicine 9 37                             “ 
Medicine-Pediatrics 4 50                             “ 
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Table 2. Antithrombotic Therapy discordant from AFDST recommendations 
 Antithrombotic Therapy 
 Discordant in 2014  Discordant in 2015  
 (%) (n) (%) (n) 
All Practices 41.9  626/1493 40.6    (p=0.10) 606/1493 
     
Intervention Practices 41.8 335/801 41.1      (p=0.51) 329/801 
Control Practices 42.1 291/692 40.0      (p=0.07) 277/692 
     
Aspirin or No Anticoagulant Therapy 
Among Patients for whom OAT was 
recommended 
    
Intervention Practices 44.7 296/663 44.5      (p=0.59) 300/674 
Control Practices 44.8 253/565 43.5      (p=0.27) 247/568 
     
Antithrombotic Therapy Among 
Patients for whom No Antithrombotic 
Therapy was recommended † 
    
Intervention Practices 60.0 30/50 59.1      (p=0.65) 26/44 
Control Practices 43.2 19/44 32.5      (p=0.56) 13/40 
     
Oral Anticoagulant Therapy Among 
Patients for whom No Antithrombotic 
Therapy was recommended † 
    
Intervention Practices 22.7 15/66 21.1      (p=0.56) 12/57 
Control Practices 14.3 8/56 10.9      (p=1.00) 6/55 
†Although the denominators for both of these sections are patients for whom no antithrombotic 
therapy was recommended, the numbers may be slightly different since recommendations are not 
made unless the strategy, in this case “No Antithrombotic Therapy” generates a gain of ≥ 0.1 QALYs. 
Since the comparator strategies are different in these two groups (antithrombotic therapy for the 
middle rows and OAT for the bottom rows), the composition of patients in the denominators may be 
slightly different. 
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Table 3. Antithrombotic Therapy discordant from AFDST recommendations – by subgroup 
Intervention Group Antithrombotic Therapy 
 Discordant in 2014  Discordant in 2015 
 (%) (n) (%) (n) 
Practice Rating (readiness 
for change) –  
high enthusiasm 
moderate enthusiasm 
low enthusiasm 
 
 
41.1 
42.9 
43.3 
 
 
353/859 
166/387 
107/247 
 
 
39.2    (p=0.09) 
41.1    (p=0.25) 
44.53  (p=0.51) 
 
 
337/859 
159/387 
110/247 
     
Faculty type – 
Faculty 
Non-faculty 
resident 
 
42.0 
41.6 
44.2 
 
407/970 
142/341 
76/172 
 
40.0    (p=0.04) 
43.4    (p=0.24) 
39.5    (p=0.14) 
 
388/970 
148/341 
68/172 
     
Faculty Specialty – 
Internal Medicine 
Family Medicine 
Medicine-Pediatrics 
 
42.4 
38.8 
47.7 
 
390/919 
150/387 
84/176 
 
42.1    (p=0.75) 
37.2    (p=0.27) 
40.9    (p=0.01) 
 
387/919 
144/387 
72/176 
     
Among Patients for whom 
AFSDT Report was 
reviewed 
63.3 152/240 58.3    (p=0.02) 140/240 
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Table 4. “Appropriate” Thromboprophylaxis in 2015, among patients with Discordant Care 
in 2014 
 Concordant in 2015 
(%), (n) 
  
All Practices 13.1                82/626 
  
Treatment Group –  
Intervention Practices 
Control Practices 
(p=0.79) 
13.4                45/335 
12.7                37/291 
Practice Site –  
A 
B 
C 
D 
E 
Resident Practice 
(p=0.08) 
10.9                15/138 
9.9                    7/71 
0                       0/2 
11.6                 5/43 
11.1                 2/18 
25.4               16/63 
  
Practice Rating (readiness for 
change) –  
high enthusiasm 
moderate enthusiasm 
low enthusiasm 
(p=0.27) 
 
14.4                51/353 
13.2                22/166 
8.4                    9/107 
  
Faculty type –  
Faculty 
Non-faculty 
resident 
(p=0.001) 
13.0                53/407 
7.0                  10/142 
25.0                19/76 
  
Faculty Specialty –  
Internal Medicine 
Family Medicine 
Medicine-Pediatrics 
(p=0.05) 
11.8                46/390 
12.0                18/150 
21.4                18/84 
  
Among Patients for whom AFSDT 
Report was  
Reviewed 
Not Reviewed 
(p=0.74) 
 
12.7                20/152 
14.0                26/183 
